JP2023552816A5 - - Google Patents
Info
- Publication number
- JP2023552816A5 JP2023552816A5 JP2023534899A JP2023534899A JP2023552816A5 JP 2023552816 A5 JP2023552816 A5 JP 2023552816A5 JP 2023534899 A JP2023534899 A JP 2023534899A JP 2023534899 A JP2023534899 A JP 2023534899A JP 2023552816 A5 JP2023552816 A5 JP 2023552816A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063124064P | 2020-12-11 | 2020-12-11 | |
| US63/124,064 | 2020-12-11 | ||
| US202063130106P | 2020-12-23 | 2020-12-23 | |
| US63/130,106 | 2020-12-23 | ||
| PCT/US2021/062946 WO2022125982A1 (en) | 2020-12-11 | 2021-12-10 | Compositions and methods for reducing mhc class ii in a cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023552816A JP2023552816A (ja) | 2023-12-19 |
| JP2023552816A5 true JP2023552816A5 (https=) | 2024-12-19 |
Family
ID=80168106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023534899A Pending JP2023552816A (ja) | 2020-12-11 | 2021-12-10 | 細胞内のｍｈｃクラスｉｉを低減する組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240016934A1 (https=) |
| EP (1) | EP4259783A1 (https=) |
| JP (1) | JP2023552816A (https=) |
| KR (1) | KR20230130635A (https=) |
| AU (1) | AU2021396403A1 (https=) |
| CA (1) | CA3204997A1 (https=) |
| CL (2) | CL2023001688A1 (https=) |
| CO (1) | CO2023008922A2 (https=) |
| CR (1) | CR20230303A (https=) |
| IL (1) | IL303505A (https=) |
| MX (1) | MX2023006878A (https=) |
| TW (1) | TW202235617A (https=) |
| WO (1) | WO2022125982A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4544058A1 (en) * | 2022-06-23 | 2025-04-30 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of ciita expression |
| US20240189355A1 (en) * | 2022-11-14 | 2024-06-13 | WUGEN, Inc. | Hypoimmunogenic cells having targeted modifications in mhc class-i genes and methods of use |
| CN118922551A (zh) * | 2023-01-30 | 2024-11-08 | 南京北恒生物科技有限公司 | 用于CRISPR-Cas基因编辑系统的方法及组合物 |
| KR102740042B1 (ko) | 2023-07-12 | 2024-12-06 | ㈜바이오솔빅스 | 인간 전분화능 줄기세포로 유래된 심장 오가노이드 제조방법, 효능 및 독성 평가 기술 |
| WO2025038646A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Cd70 car-t compositions and methods for cell-based therapy |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025038642A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying cd70 |
| IL326191A (en) | 2023-08-14 | 2026-03-01 | Intellia Therapeutics Inc | Compositions and methods for genetic modification of transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025049432A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01 |
| WO2025049481A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025255308A1 (en) | 2024-06-07 | 2025-12-11 | Intellia Therapeutics, Inc. | Cd8 co-receptor chimeric polypeptides in tcr cell therapy |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| JP3131222B2 (ja) | 1991-12-24 | 2001-01-31 | アイシス・ファーマシューティカルス・インコーポレーテッド | ギャップを有する２′修飾オリゴヌクレオチド |
| JPH10500310A (ja) | 1994-05-19 | 1998-01-13 | ダコ アクティーゼルスカブ | 淋菌及びトラコーマ クラミジアの検出のためのｐｎａ プローブ |
| CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| DK2931891T3 (da) | 2012-12-17 | 2019-08-19 | Harvard College | Rna-styret modificering af menneskelige genomer |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| KR20230156800A (ko) | 2015-03-03 | 2023-11-14 | 더 제너럴 하스피탈 코포레이션 | 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제 |
| WO2017093969A1 (en) * | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| LT3436077T (lt) | 2016-03-30 | 2025-06-25 | Intellia Therapeutics, Inc. | Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| SG10202106058WA (en) | 2016-12-08 | 2021-07-29 | Intellia Therapeutics Inc | Modified guide rnas |
| EP4029943A1 (en) | 2017-05-08 | 2022-07-20 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
| MX2019013514A (es) * | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| US20230140670A1 (en) | 2017-09-29 | 2023-05-04 | Intellia Therapeutics, Inc. | Formulations |
| EP3724326A1 (en) * | 2017-12-11 | 2020-10-21 | Editas Medicine, Inc. | Cpf1-related methods and compositions for gene editing |
| WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
| US11447769B2 (en) | 2018-03-27 | 2022-09-20 | The Trustees Of The University Of Pennsylvania | Modified immune cells having enhanced function and methods for screening for same |
| WO2019237035A1 (en) * | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| AU2019282824C1 (en) | 2018-06-08 | 2026-04-23 | Intellia Therapeutics, Inc. | Modified guide RNAS for gene editing |
| EP3581200A1 (en) | 2018-06-13 | 2019-12-18 | GEMoaB Monoclonals GmbH | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| IL282267B2 (en) | 2018-10-15 | 2026-03-01 | Univ Massachusetts | Programmed DNA editing by chimeric deaminase-nme2cas9 proteins |
| CN113227374A (zh) | 2018-10-16 | 2021-08-06 | 因特利亚治疗公司 | 用于免疫疗法的组合物和方法 |
| WO2020092057A1 (en) | 2018-10-30 | 2020-05-07 | Yale University | Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells |
| KR20210128440A (ko) * | 2019-02-15 | 2021-10-26 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 범용 공여자 줄기 세포 및 관련 방법 |
-
2021
- 2021-12-10 MX MX2023006878A patent/MX2023006878A/es unknown
- 2021-12-10 CR CR20230303A patent/CR20230303A/es unknown
- 2021-12-10 IL IL303505A patent/IL303505A/en unknown
- 2021-12-10 JP JP2023534899A patent/JP2023552816A/ja active Pending
- 2021-12-10 EP EP21852082.3A patent/EP4259783A1/en active Pending
- 2021-12-10 KR KR1020237022783A patent/KR20230130635A/ko not_active Withdrawn
- 2021-12-10 CA CA3204997A patent/CA3204997A1/en active Pending
- 2021-12-10 TW TW110146323A patent/TW202235617A/zh unknown
- 2021-12-10 WO PCT/US2021/062946 patent/WO2022125982A1/en not_active Ceased
- 2021-12-10 AU AU2021396403A patent/AU2021396403A1/en not_active Abandoned
-
2023
- 2023-06-09 CL CL2023001688A patent/CL2023001688A1/es unknown
- 2023-06-09 US US18/332,390 patent/US20240016934A1/en active Pending
- 2023-07-05 CO CONC2023/0008922A patent/CO2023008922A2/es unknown
- 2023-10-17 CL CL2023003085A patent/CL2023003085A1/es unknown